An article titled, “Prior GLP-1 agonist use is not associated with adverse inpatient critical care outcomes: A propensity-matched analysis,” was published in Society of Hospital Medicine’s Journal of Hospital Medicine by authors Albert K. Park MD, Jason Hom MD, Javier Lorenzo MD, Vidya Rao MD, Gavin Hui MD, PhD, Matthew Vickers FRACGP, MBBS, Neera Ahuja MD, FACP, SFHM. The authors are affiliated with Stanford University and Atropos Health.
Short Summary:
Glucagon-like peptide-1 (GLP-1) agonists are increasingly prescribed for obesity and type 2 diabetes. GLP-1 agonists influence body composition through effects on both fat mass and fat-free mass. Given that critically ill patients experience severe protein catabolism and commonly develop intensive care unit (ICU)-acquired weakness, questions arise about outcomes when metabolic demands are high during critical illness. This retrospective cohort study uses Stanford Health Care data from January 2015 to July 2024 to examine the relationship between prior GLP-1 agonist use and critical care outcomes.